tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Maze Therapeutics prices 4M shares at $16.25 in private placement
PremiumThe FlyMaze Therapeutics prices 4M shares at $16.25 in private placement
13h ago
Maze Therapeutics Appoints Misbah Tahir as CFO
Premium
Company Announcements
Maze Therapeutics Appoints Misbah Tahir as CFO
10d ago
Maze Therapeutics appoints Tahir as Chief Financial Officer
Premium
The Fly
Maze Therapeutics appoints Tahir as Chief Financial Officer
10d ago
Maze Therapeutics: Promising Innovations in PKU and CKD Treatment with MZE782
PremiumRatingsMaze Therapeutics: Promising Innovations in PKU and CKD Treatment with MZE782
29d ago
Maze Therapeutics reports Q2 EPS (77c), consensus ($1.15)
Premium
The Fly
Maze Therapeutics reports Q2 EPS (77c), consensus ($1.15)
1M ago
Maze Therapeutics, Inc.: Buy Rating Initiated on Precision Nephrology Potential and Undervalued Stock
Premium
Ratings
Maze Therapeutics, Inc.: Buy Rating Initiated on Precision Nephrology Potential and Undervalued Stock
2M ago
Positive Outlook for Maze Therapeutics: Buy Rating Reiterated Amid Promising Drug Developments and Strong Financial Position
PremiumRatingsPositive Outlook for Maze Therapeutics: Buy Rating Reiterated Amid Promising Drug Developments and Strong Financial Position
4M ago
Positive Outlook for Maze Therapeutics: Promising Pipeline and Strong Financial Position Justify Buy Rating
Premium
Ratings
Positive Outlook for Maze Therapeutics: Promising Pipeline and Strong Financial Position Justify Buy Rating
5M ago
Maze Therapeutics reports Q4 EPS ($18.32) vs ($11.46) last year
Premium
The Fly
Maze Therapeutics reports Q4 EPS ($18.32) vs ($11.46) last year
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100